Table 4.
Predictors of prescription of ≥50% of target dose among eligible patients
| Covariate | Unadjusted odds ratio (95% CI) | Adjusted odds ratio |
|---|---|---|
| ACE‐I/ARB | ||
| Age (per 10 year increase) | 0.72 (0.61–0.84), P < 0.0001 | 0.71 (0.59–0.85), P < 0.001* |
| Female sex | 0.90 (0.53–1.51), P = 0.69 | P = 0.88 |
| History of heart failure | 0.61 (0.37–0.98), P = 0.04 | 0.56 (0.32–0.96), P = 0.04* |
| History of myocardial infarction | 0.65 (0.37–1.16), P = 0.14 | P = 0.15 |
| LVEF (per 10% increase) | 1.03 (0.89–1.19), P = 0.70 | P = 0.22 |
| Charlson co‐morbidity score 3–4 vs. ≤2 | 0.96 (0.57–1.63), P = 0.89 | P = 0.22 |
| Charlson co‐morbidity score ≥5 vs. ≤2 | 0.50 (0.13–1.93), P = 0.32 | P = 0.22 |
| Systolic BP (per 10 mmHg increase) | 1.06 (0.96–1.16), P = 0.24 | 1.16 (1.03–1.29), P = 0.01* |
| eGFR (per 10 mL/min/1.73 m increase) | 1.15 (1.04–1.28), P = 0.008 | P = 0.82 |
| Serum potassium (per mmol/L increase) | 2.20 (1.24–3.90), P = 0.007 | 1.95 (1.05–3.63), P = 0.04* |
| Cardiologist care | 2.71 (1.66–4.43), P < 0.0001 | 2.40 (1.40–4.13), P = 0.002* |
| Beta‐blocker | ||
| Age (per 10 year increase) | 0.81 (0.71–0.93), P = 0.003 | 0.85 (0.74–0.99), P = 0.04* |
| Female sex | 0.96 (0.60–1.53), P = 0.85 | P = 0.47 |
| History of heart failure | 2.56 (1.64–3.98), P < 0.0001 | 2.57 (1.63–4.05), P < 0.0001* |
| History of myocardial infarction | 0.73 (0.44–1.23), P = 0.24 | P = 0.23 |
| History of atrial fibrillation | 1.21 (0.79–1.86), P = 0.38 | P = 0.06 |
| LVEF (per 10% increase) | 0.97 (0.75–1.25), P = 0.80 | P = 0.59 |
| Charlson co‐morbidity score 3–4 vs. ≤2 | 0.86 (0.54–1.38), P = 0.54 | P = 0.85 |
| Charlson co‐morbidity score ≥5 vs. ≤2 | 0.62 (0.24–1.63), P = 0.33 | P = 0.85 |
| Systolic BP (per 10 mmHg increase) | 0.94 (0.87–1.02), P = 0.13 | P = 0.93 |
| Heart rate (per 10 bpm increase) | 0.98 (0.88–1.10), P = 0.77 | P = 0.50 |
| Cardiologist care | 1.74 (1.13–2.69), P = 0.01 | 1.64 (1.02–2.62), P = 0.04* |
| MRA | ||
| Age (per 10 year increase) | 0.72 (0.62–0.85), P < 0.0001 | P = 0.20 |
| Female sex | 0.59 (0.33–1.09), P = 0.09 | P = 0.60 |
| History of heart failure | 1.63 (0.96–2.77), P = 0.07 | P = 0.08 |
| History of myocardial infarction | 1.15 (0.62–2.12), P = 0.66 | P = 0.29 |
| LVEF (per 10% increase) | 0.54 (0.39–0.75), P < 0.001 | 0.51 (0.37–0.72), P < 0.001* |
| Charlson co‐morbidity score 3–4 vs. ≤2 | 0.66 (0.36–1.20), P = 0.17 | P = 0.47 |
| Charlson co‐morbidity score ≥5 vs. ≤2 | 0.56 (0.15–2.00), P = 0.37 | P = 0.47 |
| Systolic BP (per 10 mmHg increase) | 0.90 (0.81–0.99), P = 0.04 | P = 0.83 |
| eGFR (per 10 mL/min/1.73 m increase) | 1.10 (0.99–1.21), P = 0.08 | P = 0.75 |
| Serum potassium (per mmol/L increase) | 1.08 (0.59–1.96), P = 0.80 | P = 0.24 |
| Cardiologist care | 3.14 (1.82–5.43), P < 0.0001 | 2.95 (1.68–5.18), P < 0.001* |
ACE‐I/ARB, angiotensin‐converting enzyme inhibitors or angiotensin receptor blocker; BP, blood pressure; CI, confidence interval; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; MRA, mineralocorticoid receptor antagonist.
*
P < 0.05 and included in final model.